Financhill
Buy
57

ITCI Quote, Financials, Valuation and Earnings

Last price:
$127.94
Seasonality move :
3.96%
Day range:
$127.80 - $128.19
52-week range:
$62.78 - $128.19
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
21.00x
P/B ratio:
11.84x
Volume:
1.4M
Avg. volume:
4.5M
1-year change:
77.55%
Market cap:
$13.6B
Revenue:
$462.2M
EPS (TTM):
-$0.87

Analysts' Opinion

  • Consensus Rating
    Intra-Cellular Therapies has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 9 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $132.73, Intra-Cellular Therapies has an estimated upside of 3.84% from its current price of $127.82.
  • Price Target Downside
    According to analysts, the lowest downside price target is $132.00 representing 100% downside risk from its current price of $127.82.

Fair Value

  • According to the consensus of 12 analysts, Intra-Cellular Therapies has 3.84% upside to fair value with a price target of $132.73 per share.

ITCI vs. S&P 500

  • Over the past 5 trading days, Intra-Cellular Therapies has underperformed the S&P 500 by -0.82% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Intra-Cellular Therapies does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Intra-Cellular Therapies has grown year-over-year revenues for 15 quarters straight. In the most recent quarter Intra-Cellular Therapies reported revenues of $175.2M.

Earnings Growth

  • Intra-Cellular Therapies has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Intra-Cellular Therapies reported earnings per share of -$0.25.
Enterprise value:
12.5B
EV / Invested capital:
--
Price / LTM sales:
21.00x
EV / EBIT:
--
EV / Revenue:
20.47x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-199.40x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$565.5M
Return On Assets:
-8.93%
Net Income Margin (TTM):
-14.1%
Return On Equity:
-10.58%
Return On Invested Capital:
-10.58%
Operating Margin:
-22.18%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $187.2M $418.1M $612.8M $125.8M $175.2M
Gross Profit $171M $388.3M $565.5M $116.7M $159.9M
Operating Income -$302.2M -$172.7M -$121.6M -$29.7M -$38.8M
EBITDA -$301.6M -$172.2M -$121.1M -$29.6M -$38.7M
Diluted EPS -$3.32 -$1.61 -$0.87 -$0.25 -$0.25
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $744.9M $533.2M $759.8M $702.4M $1.3B
Total Assets $771.3M $557M $782M $717.7M $1.3B
Current Liabilities $38M $49.9M $77.4M $103.1M $166.1M
Total Liabilities $61.9M $70.2M $96.6M $117M $179.6M
Total Equity $709.4M $486.8M $685.4M $600.7M $1.1B
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$304.2M -$161.3M -$62.2M -$25.3M -$26.5M
Cash From Investing -$127.1M $108.4M -$137.8M -$20.2M -$209.2M
Cash From Financing $460.9M $17M $564.9M $2.6M $6.7M
Free Cash Flow -$305M -$161.6M -$62.9M -$25.5M -$27.2M
ITCI
Sector
Market Cap
$13.6B
$43.4M
Price % of 52-Week High
99.71%
48.26%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
77.55%
-34.26%
Beta (5-Year)
0.718
0.749
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $127.46
200-day SMA
Buy
Level $82.56
Bollinger Bands (100)
Buy
Level 72.63 - 112.65
Chaikin Money Flow
Sell
Level -22.9M
20-day SMA
Buy
Level $127.17
Relative Strength Index (RSI14)
Buy
Level 83.15
ADX Line
Buy
Level 69.82
Williams %R
Neutral
Level -28.2443
50-day SMA
Buy
Level $105.05
MACD (12, 26)
Buy
Level 6.11
25-day Aroon Oscillator
Buy
Level 96
On Balance Volume
Neutral
Level 125.7M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (27.9599)
Buy
CA Score (Annual)
Level (0.3768)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (0.5989)
Buy
Piotroski F Score (Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Stock Forecast FAQ

In the current month, ITCI has received 3 Buy ratings 9 Hold ratings, and 0 Sell ratings. The ITCI average analyst price target in the past 3 months is $132.73.

  • Where Will Intra-Cellular Therapies Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Intra-Cellular Therapies share price will rise to $132.73 per share over the next 12 months.

  • What Do Analysts Say About Intra-Cellular Therapies?

    Analysts are divided on their view about Intra-Cellular Therapies share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Intra-Cellular Therapies is a Sell and believe this share price will drop from its current level to $132.00.

  • What Is Intra-Cellular Therapies's Price Target?

    The price target for Intra-Cellular Therapies over the next 1-year time period is forecast to be $132.73 according to 12 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 9 analysts rate the stock a Hold.

  • Is ITCI A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Intra-Cellular Therapies is a Hold. 9 of 12 analysts rate the stock a Hold at this time.

  • How Can I Buy Shares Of ITCI?

    You can purchase shares of Intra-Cellular Therapies via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Intra-Cellular Therapies shares.

  • What Is The Intra-Cellular Therapies Share Price Today?

    Intra-Cellular Therapies was last trading at $127.94 per share. This represents the most recent stock quote for Intra-Cellular Therapies. Yesterday, Intra-Cellular Therapies closed at $127.82 per share.

  • How To Buy Intra-Cellular Therapies Stock Online?

    In order to purchase Intra-Cellular Therapies stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Clorox’s Dividend Worth It?
Is Clorox’s Dividend Worth It?

Clorox (NYSE:CLX) is the parent company of some of the…

Is ORCL Stock a Buy Sell or Hold?
Is ORCL Stock a Buy Sell or Hold?

High-tech plays, nowadays, have shifted to the cloud. A laundry…

Is UPS High Dividend Safe?
Is UPS High Dividend Safe?

Although full-year profits dipped, Q4 2024 revenue inched up 1.5%…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 116x

Sell
47
Is MSFT Stock a Buy?

Market Cap: $3T
P/E Ratio: 35x

Alerts

Buy
87
PCOR alert for Feb 15

Procore Technologies [PCOR] is up 16.3% over the past day.

Buy
54
DKNG alert for Feb 15

DraftKings [DKNG] is up 15.24% over the past day.

Sell
30
TWLO alert for Feb 15

Twilio [TWLO] is down 15.01% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock